Sage Therapeutics Inc. (NASDAQ:SAGE) CFO Kimi Iguchi sold 1,500 shares of Sage Therapeutics stock in a transaction dated Friday, November 11th. The shares were sold at an average price of $50.59, for a total value of $75,885.00. Following the completion of the transaction, the chief financial officer now directly owns 79,739 shares of the company’s stock, valued at $4,033,996.01. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Kimi Iguchi also recently made the following trade(s):

  • On Wednesday, September 7th, Kimi Iguchi sold 2,500 shares of Sage Therapeutics stock. The shares were sold at an average price of $40.93, for a total value of $102,325.00.

Sage Therapeutics Inc. (NASDAQ:SAGE) opened at 52.00 on Thursday. The stock’s 50 day moving average price is $44.80 and its 200 day moving average price is $38.88. The firm’s market capitalization is $1.93 billion. Sage Therapeutics Inc. has a 52-week low of $26.28 and a 52-week high of $62.64.

Sage Therapeutics (NASDAQ:SAGE) last released its quarterly earnings data on Thursday, November 3rd. The biopharmaceutical company reported ($1.15) earnings per share for the quarter, missing the consensus estimate of ($1.10) by $0.05. On average, equities analysts anticipate that Sage Therapeutics Inc. will post ($4.35) earnings per share for the current fiscal year.

SAGE has been the subject of a number of research analyst reports. BMO Capital Markets reaffirmed a “buy” rating and issued a $57.00 price target on shares of Sage Therapeutics in a report on Friday, August 12th. Stifel Nicolaus initiated coverage on Sage Therapeutics in a report on Monday. They issued a “buy” rating and a $90.00 price target for the company. Cowen and Company reaffirmed a “buy” rating on shares of Sage Therapeutics in a report on Thursday, November 3rd. Canaccord Genuity set a $110.00 price target on Sage Therapeutics and gave the company a “buy” rating in a report on Tuesday, September 6th. Finally, Zacks Investment Research raised Sage Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, August 26th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eleven have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $69.54.

Hedge funds have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp raised its stake in Sage Therapeutics by 13.0% in the second quarter. Bank of New York Mellon Corp now owns 104,010 shares of the biopharmaceutical company’s stock valued at $3,134,000 after buying an additional 11,978 shares during the period. Alps Advisors Inc. raised its stake in Sage Therapeutics by 25.1% in the second quarter. Alps Advisors Inc. now owns 45,044 shares of the biopharmaceutical company’s stock valued at $1,357,000 after buying an additional 9,036 shares during the period. Candriam Luxembourg S.C.A. raised its stake in Sage Therapeutics by 7.2% in the second quarter. Candriam Luxembourg S.C.A. now owns 74,000 shares of the biopharmaceutical company’s stock valued at $2,230,000 after buying an additional 5,000 shares during the period. RS Investment Management Co. LLC raised its stake in Sage Therapeutics by 1.8% in the second quarter. RS Investment Management Co. LLC now owns 586,826 shares of the biopharmaceutical company’s stock valued at $17,681,000 after buying an additional 10,435 shares during the period. Finally, Eagle Asset Management Inc. raised its stake in Sage Therapeutics by 3.2% in the second quarter. Eagle Asset Management Inc. now owns 873,924 shares of the biopharmaceutical company’s stock valued at $26,331,000 after buying an additional 27,319 shares during the period. 85.82% of the stock is currently owned by institutional investors and hedge funds.

Sage Therapeutics Company Profile

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. Its lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the GABAA receptor.

5 Day Chart for NASDAQ:SAGE

Receive News & Stock Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related stocks with our FREE daily email newsletter.